

SAMPLE CODING

RET Fusion-positive Metastatic Non-small Cell Lung Cancer (mNSCLC)

TYPE	CODE		DESCRIPTION	
Diagnosis: ICD-10-CM	C34.00		Malignant neoplasm of unspecified main bronchus	
	C34.01		Malignant neoplasm of right main bronchus	
	C34.02		Malignant neoplasm of left main bronchus	
	C34.10		Malignant neoplasm of upper lobe, unspecified bronchus or lung	
	C34.11		Malignant neoplasm of upper lobe, right bronchus or lung	
	C34.12		Malignant neoplasm of upper lobe, left bronchus or lung	
	C34.2		Malignant neoplasm of middle lobe, bronchus or lung	
	C34.30		Malignant neoplasm of lower lobe, unspecified bronchus or lung	
	C34.31		Malignant neoplasm of lower lobe, right bronchus or lung	
	C34.32		Malignant neoplasm of lower lobe, left bronchus or lung	
	C34.80		Malignant neoplasm of overlapping sites of unspecified bronchus and lung	
	C34.81		Malignant neoplasm of overlapping sites of right bronchus and lung	
	C34.82		Malignant neoplasm of overlapping sites of left bronchus and lung	
	C34.90		Malignant neoplasm of unspecified part of unspecified bronchus and lung	
	C34.91		Malignant neoplasm of unspecified part of right bronchus and lung	
	C34.92		Malignant neoplasm of unspecified part of left bronchus and lung	
	Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.	10-digit	11-digit	
		50242-210-60	50242-0210-60	GAVRETO 100-mg capsule, bottle of 60
50242-210-90		50242-0210-90	GAVRETO 100-mg capsule, bottle of 90	

ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

GAVRETO® is discovered by Blueprint Medicines and co-commercialized by Genentech with Blueprint Medicines Corporation in the US. Blueprint Medicines and GAVRETO are trademarks of Blueprint Medicines Corporation. The Access Solutions logo is a registered trademark of Genentech, Inc.

Please see Important Safety Information in full [Prescribing Information](#).